Ra Medical Systems to Report Third Quarter 2021 Financial Results on November 15, 2021

Ra Medical Systems, Inc. (NYSE American: RMED) announces that it will report third quarter 2021 financial results after market close on Monday, November 15. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

About Ra Medical Systems

Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA breaks down plaque to its fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.